One such approach being utilized in CLL is time-limited venetoclax plus anti-CD20 monoclonal antibody therapy, which could potentially reduce the risk of acquisition of BCL2 mutations by minimizing the duration of venetoclax exposure (49). The gene discussed is BCL2; the disease is B-cell chronic lymphocytic leukemia.